Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice by Tatiani Uceli Maioli et al.
Maioli et al. Journal of Negative Results in BioMedicine 2014, 13:6
http://www.jnrbm.com/content/13/1/6RESEARCH Open AccessPretreatment with Saccharomyces boulardii does
not prevent the experimental mucositis in
Swiss mice
Tatiani Uceli Maioli1, Brenda de Melo Silva1, Michelle Nobre Dias1, Nivea Carolina Paiva2,
Valbert Nascimento Cardoso3, Simone Odilia Fernandes3, Cláudia Martins Carneiro2,
Flaviano dos Santos Martins4 and Simone de Vasconcelos Generoso1*Abstract
Background: The antimetabolite chemotherapy 5-Fluorouracil is one of the most commonly prescribed drugs in
clinical cancer treatment. Although this drug is not specific for cancer cells and also acts on healthy cells, it can
cause mucositis, a common collateral effect. Dysbiosis has also been described in 5-fluorouracil-induced mucositis
and is likely to contribute to the overall development of mucositis. In light of this theory, the use of probiotics could
be a helpful strategy to alleviate mucositis. So the aim of this study was evaluate the impact of the probiotic
Saccharomyces boulardii in a model of mucositis.
Results: After induced of mucositis, mice from the Mucositis groups showed a decrease in food consumption (p < 0.05)
and therefore had a greater weight loss (p < 0.05). The treatment with Saccharomyces boulardii did not reverse this effect
(p > 0.05). Mucositis induced an increase in intestinal permeability and intestinal inflammation (p < 0.05). There were no
differences in mucosal lesions, intestinal permeability and sIgA secretion (p > 0.05) in mice pretreated with S. boulardii.
Conclusions: S. boulardii was not able to prevent the effects of experimental mucositis induced by 5- Fluorouracil.
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The antimetabolite chemotherapy 5-Fluorouracil (5-FU)
is one of the most commonly prescribed drugs in clinical
cancer treatment [1]. It is used in many types of cancer,
including breast, pancreas, gastrointestinal, head and neck
[2-4]. Although this drug is not specific for cancer cells and
also acts on healthy cells, it can cause mucositis, a common
collateral effect of cancer chemotherapy and radiotherapy.
This problem can affect the entire gastrointestinal tract,
causing odynophagia, vomiting, abdominal pain and diar-
rhea [5,6]. These symptoms are associated with decreased
food consumption, weight loss and diminished nutritional
status [7]. Approximately 40% of patients are affected by
mucositis when they receive normal doses of chemother-
apy, and almost all patients have this problem when they* Correspondence: simonenutufmg@gmail.com
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unless otherwise stated.receive higher doses, for example, in cases of treatment for
leukemia and bone marrow transplantation [8]. Mucositis
has a huge clinical and economic impact because it in-
creases the prevalence of infection and hemorrhage and
prolongs the time and cost of hospitalization [6].
Treatment with 5-FU causes significant villus shorten-
ing and decreases the villus/crypt ratio in both human
and animal models [9,10]. This alteration in the intes-
tinal morphology can disrupt physical barriers and favor
the translocation of microorganisms, increasing the pos-
sibility of sepsis [11,12].
Dysbiosis has also been described in 5-FU-induced
mucositis and is likely to contribute to the overall devel-
opment of mucositis [13]. In light of this theory, the use
of probiotics could be a helpful strategy to alleviate mu-
cositis. Probiotics have been investigated as a therapeutic
approach in a range of disorders, including inflammatory
bowel disease and other intestinal problems [14,15]. Pro-
biotics are defined as living microorganisms, which whentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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to the host [16]. Saccharomyces boulardii is probiotic yeast
that has been proven to be effective in the treatment of a
variety of diarrheal diseases. This yeast has been success-
fully used for the prevention and treatment of antibiotic-
associated diarrhea [17-21].
Previous results of our research showed that S. boulardii
was able to reduce intestinal permeability and bacterial
translocation in a model of intestinal obstruction [14]. To
study a novel way to alleviate mucositis, we decided to in-
vestigate the effects of probiotic S. boulardii in preventing
the symptoms caused by 5-FU treatment in an experimen-
tal model of mucositis.
Results
Food consumption and weight during treatment
Food consumption and weight gain were measured during
the experiments. There was no difference in the amount
of food consumed among the groups treated with saline
or S. boulardii (Sb). After injection of 5-FU, mice from the
Mucositis groups showed a decrease in food consump-
tion, and the treatment with Sb did not reverse this
effect (Figure 1). As was expected, there were weight
losses after mucositis induction (Figure 2A and B). Mice
from the Mucositis groups lost approximately 3 g in
3 days (Figure 2B). Pre-treatment with S. boulardii did
not prevent this effect.
Intestinal permeability and histological analyses
Intestinal permeability is one of the main problems caused
by chemotherapy, including treatment with 5-FU. We in-
vestigated whether pre-treatment with Sb could alleviate
this problem. Figure 3 shows that 5-FU increased intes-
tinal permeability measured by 99mDTPA in the blood. NoFigure 1 Variation in food consumption. Mice received commercial cho
consumed were measured every day. (*) Indicates statistically significant di
experiments. Sb - S. boulardii; BM - before mucositis induction; AM - after mstatistical difference was observed between the Mucositis
and Mucositis + Sb groups for this response.
Histological analyses were performed to confirm the
permeability data. The Control and Control + Sb mice
had healthy small intestinal mucosa with no inflammatory
infiltration in the mucosal, sub mucosal or muscular layers.
The villus/crypt ratio was the same in mice treated with
S. boulardii and those not treated. Thus, the daily probiotic
treatment did not alter gut mucosal morphology (Figure 4A
and C). The integrity of the mucosa was lost in mice that
received 5-FU (Figure 4B and D). Both Mucositis groups
showed lesions in the small intestine, particularly in the
jejunum and ileum. They also had marked cell infiltration
in the lamina propria, decreased villus size, and Paneth cell
hypersecretion, as well as inflammation in the submucosa
and muscular layers. These data confirm the effect of 5-FU
in mucositis development. There were no significant differ-
ences between mice pre-treated or not with S. boulardii.
To confirm the data from the histological slides, mor-
phometric analyses were performed and showed decreases
in villus height in both mucositis groups, but there were
no statistical differences between the Mucositis and
Mucositis + Sb groups (Figure 5A). In none of the groups
were differences in crypt height or in villus thickness
(Figures 5B and C). There were also no differences in
the villus/crypt ratio between control groups and muco-
sitis groups (Figure 5D). These results suggest that 5-FU
has more effect on the villus than the crypt.IgA secretion
IgA secretion in the small intestine was also investigated.
We did not observe any statistical differences among the
groups (Figure 6).w ad libitum during the entire experiment. The amounts of food
fferences (p < 0.05), n = 7; data are representative of three different
ucositis induction.
Figure 2 Weight variation during the experiment. Mice from the
Control + Sb and Mucositis + Sb groups were pre-treated with 108 CFU
of S. boulardii by gavage for 10 days; other groups received saline by
gavage. On day 11 of the experiment, mice from the Mucositis group
received an intraperitoneal injection of 300 mg/kg of 5-FU. The weights
were monitored daily until day 13 (A), and weight losses represent the
difference between the weight on day 11 and day 13 (B). (*) Indicates
statistically significant differences (p < 0.05), n = 7; data are representative
of three different experiments.
Figure 3 Effect of pre-treatment with S. boulardii on intestinal
permeability. Mice from the Control + Sb and Mucositis + Sb
groups were pre-treated with 108 CFU of S. boulardii by gavage for
10 days; other groups received saline by gavage. On the 11th day of
the experiment, mice from Mucositis group received an intraperitoneal
injection of 300 mg/kg of 5-FU. After 72 h, all received 99mDNTP by
gavage, and four hours later, they were given general anesthesia and
had their blood collected. % dose = (counts per minute of blood/
counts per minute of administered dose). (*) Indicates statistically
significant differences (p < 0.05), n = 7; data are representative of three
different experiments.
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The current study assessed the effects of treatment with
S. boulardii on 5-FU induced intestinal damage in vivo,
an experimental model for mucositis. It has been sug-
gested that this probiotic yeast has beneficial properties,
improving the gut immune response and the intestinal
barrier [14,17,18,22]. However, our results did not show
these beneficial effects in an experimental model of muco-
sitis induced by 5-FU. There were no differences in small
intestine lesions and intestinal permeability between mice
treated with S. boulardii and those not treated.
Only few studies have evaluated the effect of probio-
tics on mucositis, and in some cases, the results arecontradictory [1,23-25]. The differences could be ex-
plained by the use of several antineoplastic agents for in-
ducing mucositis, including irinotecan, methotrexate, and
5-FU, each of which has a different mechanism of action.
This study used 5-FU at a dose of 300 mg/kg per ani-
mal. This dose was tested in our lab for Swiss mice. The
5-FU is an anti-metabolite, pyrimidine analog. Once
absorbed into the cell, 5-FU is bioactivated and inhibits
thymidylate synthetase by forming a stable, inactivating
ternary complex with the enzyme, thereby inhibiting DNA
synthesis. 5-FU also exerts its cytotoxic effects through in-
corporation into RNA and DNA, triggering apoptosis of
cancer cells and cells of healthy tissues with high rates of
cell division, including cells in the gut [26,27]. As a conse-
quence, there is increased oxidative stress, activation of
transcription factors and increased production of inflam-
matory cytokines leading to destruction of the intestinal
mucosa [28,29].
Our results showed that animals in all 4 groups had
similar levels of food intake during the treatment with
S. boulardii or saline (Figure 1). However, after the in-
duction of mucositis, the animals of the Mucositis and
Mucositis + Sb groups had significantly less food intake
than the Control groups (Figure 1) and consequently,
greater weight loss (Figure 2A). The pretreatment with
probiotic had no influence on the food intake and
weight loss. Tooley et al [24] found similar results using
Figure 4 Histological analyses of slices from the small intestine of mice pre-treated or not with S. boulardii and subjected to mucositis
induction. Normal histological aspects in mucosa were observed in mice from the Control and Control + Sb groups (A and C). Increased infiltration
of cells in the lamina propria (*) and alterations in the Lieberkün crypt glands (arrow) were observed in mice that developed mucositis (B and D).
Bar = 50 μm. The slices were stained with HE. 200x.
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animals that received probiotic treatment and were sub-
jected to mucositis induction showed weight losses
similar to those of animals that did not receive the pro-
biotic treatment. These results might be explained by
the severe inflammation, lesioning and ulceration that
can occur in mucositis induced by 5-FU and can directly
affect the food intake [8]. One other possible explan-
ation for this observation is that 5-FU induces a delay in
gastric emptying as demonstrated by Soares et al [10].
The integrity of the intestinal barrier is influenced by
changes in intestinal permeability, the function of the
mucosal immunologic system and cellular homeostasis
between the production of new enterocytes and the rate
of apoptosis of damaged enterocytes [30]. Mucositis is a
complex process that causes intestinal injuries, including
alterations in brush-border hydrolase activity, villus heights,
crypt depths, and increased apoptosis of crypt cells and
intestinal permeability [31].
Intestinal permeability is considered increased when
permeation of molecules smaller than 150 Daltons (Da)
is observed. In this study, intestinal permeability was evalu-
ated by measuring blood radioactivity after the intake of
99mTc-diethylene-triaminopentaacetate (99mTc-DTPA). Thiscompound is a disodium complex with a molecular weight
of 549 Da and a half-life of 6 hours, which satisfies the cri-
teria for a marker that can measure intestinal permeability.
In addition, 99mTc-DTPA in the blood is an accurate and
simple marker of intestinal permeability and changes in gut
function, especially in small animals in which urinary ana-
lysis is restricted by volume [32-34].
Results showed that mucositis induced an increase in
intestinal permeability (Figure 3). As demonstrated in the
same Figure, pretreatment with S. boulardii was not able
to prevent the increase in intestinal permeability. Consist-
ent with this result, histological analysis (Figure 4) showed
that animals subjected to induced mucositis presented
histological lesions with increases in the number of cells
in the lamina propria, shortened villi, hypersecretion by
the Paneth cells and inflammatory infiltrate ranging from
mild to intense in the submucosa and muscle layers. In
contrast, the control group showed histologically normal
mucosa with intact structures and a crypt/villus ratio aver-
age of 3:1 as well as healthy submucosa and muscle layers.
Pretreatment with probiotic yeast in animals with mucosi-
tis did not re-establish the tissue architecture but main-
tained the histological changes seen in the mucositis
group. These data are consistent with Mauger et al. [35]
Figure 5 Morphometrical analyses of small intestine slices from mice pre-treated or not with S. boulardii and subjected to mucositis
induction. Mice from the Control + Sb and Mucositis + Sb groups were pre-treated with 108 CFU of S. boulardii by gavage for 10 days; other
groups received saline by gavage. On the 11th day of the experiment, mice from the Mucositis group received an intraperitoneal injection of
300 mg/kg of 5-FU. A) villus mean height (μm), B) Lieberkün crypt mean height (μm), C) villus mean thickness (μm) and D) ratio between villus
and crypt mean height. (*) Indicates statistically significant differences (p < 0.05), n = 3.
Figure 6 Secretory IgA in the small intestinesof mice pre-treated
or not with S. boulardii and subjected to mucositis induction. Mice
from the Control + Sb and Mucositis + Sb groups were pre-treated with
108 CFU of S. boulardii by gavage for 10 days; other groups received
saline by gavage. On the 11th day of the experiment, mice from the
Mucositis group received an intraperitoneal injection of 300 mg/kg
of 5-FU. Small intestine fluid was collected and sIgA was measured
by ELISA.
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biotics in mucositis induced by 5-FU.
The levels of sIgA were measured, but there were no
statistical differences among the groups (Figure 6). This
result was not expected because several studies had
showed improvement of sIgA production after stimula-
tion with yeast cell wall components [15,36]. However,
5-FU leads to cellular apoptosis, decreasing the number
of B lymphocytes and other cells responsible for the in-
duction of IgA secretion in the intestine [31,37,38].
Studies with S. boulardii have shown beneficial effects
on intestinal diseases due to its anti-inflammatory action
[39] and activation of mitogen-activated protein kinases
[40,41]. In addition, the recovery of intestinal mucosa
from experimental mucositis induced by irinotecan has
been demonstrated [42]. There is also evidence of the in-
hibitory effect of live Streptococcus thermophilus TH-4
on crypt fission, suggesting therapeutic utility in the pre-
vention of disorders in mucositis induced by 5-FU [25].
For the current model, a possible explanation for the
lack of efficacy of the treatment with S. boulardii may
be the dosage, duration of treatment or inability of this
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Mauger et al. [35] did not find beneficial effects using
different species of probiotics (Lactobacillus fermentum,
Lactobacillus rhamnosus GG, and Bifidobacterium lactis
BB 12) in mucositis induced by 5-FU.
Conclusion
We conclude that the beneficial effects of probiotics differ
depending on the strain. Therefore, each strain should be
studied separately to demonstrate its effects. More studies
with S. boulardii are necessary to elucidate the mecha-




Viable S. boulardii cells from a lyophilized commercial
preparation (Floratil, Merck S.A., Rio de Janeiro, RJ, Brazil)
were used after isolation on Sabouraud dextrose agar
(Difco, Sparks, MD, USA).
Animals and experimental design
Swiss male mice from self-breeding colony, weighing be-
tween 25 and 35 g, were used in this study. The animals
were reared in an open animal cage, and water and
standard laboratory chow were given ad libitum. This
study was approved by the Ethics Committee for Animal
Experimentation of the Universidade Federal de Minas
Gerais (CETEA/UFMG) and complied with the guidelines
recommended by the Institute of Laboratory Animal Re-
sources for the care and use of laboratory animals.
The animals were divided into four groups (each group
had 7 animals, data are representative of three different ex-
periments with same n): Control, Control + Sb, Mucositis,
and Mucositis + Sb. For 10 days, mice from the Control +
Sb and Mucositis + Sb groups received 109 CFU/mL of S.
boulardii suspension in saline by gavage, final volume
0.1 mL. The Control and Mucositis groups received the
same volume of saline. Every day, the food consumption
was obtained by the difference between the amount of of-
fered chow and the residual chow. Individual amount of
food ingested were calculated from media of each cage. The
weight of the mice were measured every day with a semi
analytical balance.
Mucositis induction with 5-FU
Ten days after treatment with S. boulardii, the animals of
the Mucositis and Mucositis + Sb groups received an in-
traperitoneal injection of 300 mg/kg of 5-FU to induce
mucositis. The Control and Control + Sb groups received
an intraperitoneal injection of the same volume of sterile
saline. For three days, the animals continued receiving sa-
line or probiotic by gavage.Determination of intestinal permeability
Intestinal permeability was determined by measuring radio-
activity diffusion in the blood after oral administration of
diethylenetriaminepenta acetic acid (DTPA) labeled with
99mTc. After 10 days of treatment, all mice received 0.1 mL
of DTPA solution labeled with 18.5 MBq of 99mTc by gav-
age. Four hours after gavage, all animals were anesthetized,
and their blood was collected and placed in appropriate
tubes for radioactivity determinations [14]. Data were ex-
pressed as % dose, using the following equation: % Dose =
[(CPM of blood/CPM of administered dose)] × 100.Histopathological analyses
Animals were euthanized, all the small intestines were col-
lected, and rolls were made. The rolls were fixed with 4%
buffered formaldehyde. The material was then embedded
in paraffin, and a 4 μm section of each sample was placed
on a glass slide and stained with hematoxylin and eosin
(HE). The histological characteristics evaluated included
the general description of the section. Morphometric
analyses were used to check for inflammatory infiltration
in the lamina propria, hypersecretionin the Paneth cells,
hyperplasia of the goblet cells, submucosal and muscle
layers, and general mucosal damage. In addition, the villi
and crypts were measured. The villus height/width ratio
and the villus height⁄ crypt height ratio from intestinal epi-
thelium were also obtained.Intestinal secretory immunoglobulin A (sIgA)
After the mice had been euthanized, the small intestine
of each mouse was removed, and the contents were
withdrawn, weighed, and suspended in PBS supplemented
with an anti-protease cocktail using 500 mg of intestinal
contents per 2.0 mL. After centrifugation at 2,000 g for
30 min at 4°C, the supernatant was collected and kept
frozen at -80°C until use. Immunoglobulin levels in the
intestinal fluids were evaluated by ELISA using goat anti-
mouse IgA (Sigma Chemicals Co., St. Louis, MO, USA)
and horseradish peroxidase-conjugated goat anti-mouse
IgA (Sigma Chemical Co.). Color was developed with
o-phenylenediamine (OPD, Sigma Chemical Co.), and ab-
sorbance at 492 nm was determined with an ELISA plate
reader. The concentrations of the immunoglobulin were
determined using a purified mouse IgA standard (Southern
Biotechnology Associates, Inc.).Statistical analysis
All experiments were performed at least twice. Results
from groups were compared using ANOVA with the Dunn
test. The differences were considered statistically signifi-
cant for p < 0.05. All analyses were performed using the
program Graph Pad Prism.
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